AnaptysBio Inc. (NASDAQ:ANAB) announced that its investigational drug, rosnilimab, demonstrated a best-in-disease profile in ...

AnaptysBio announces positive results from phase 2b trial of rosnilimab to treat rheumatoid arthritis: San Diego Thursday, June 5, 2025, 18:00 Hrs [IST] AnaptysBio, Inc., a clinic ...

AnaptysBio (ANAB) hosted a webcast to discuss positive rosnilimab Phase 2b rheumatoid arthritis results and featured two leading rheumatologists, ...

The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

Format – Fireside chat and one-on-one investor meetings Date and Time – Wednesday, June 11, 2025, at 8:40am ET / 5:40am PT Live webcasts of the data release, as well as the presentation ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has hit the goals of a phase 2 rheumatoid arthritis (RA) trial. The phase 2b ...

Highlights of the poster presentation entitled, “S-4321, a novel dual-cell bidirectional PD-1:FcγRIIb selective agonist antibody for the treatment of autoimmune disease,” include ...

We are excited to explore the potential of our PD-1 inhibitor, tislelizumab ... ANKTIVA is a first-in-class IL-15 agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused ...

The absence of this motif makes mouse PD-1 significantly weaker than human PD-1. “Although many proteins in mice and humans have similar sequences, receptors in the immune system often show greater ...

WATERTOWN, Mass., November 18, 2024--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of new data for S-4321, its next ...